People · Operator
Named in public records as an officer, director or promoter · active 2016–2024 · Other Health Care, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Calyxo, Inc. | — | Other Health Care | Series C | $115.9M | $204.7M | 2018 |
| Nob Hill Therapeutics, Inc. | — | Pharma | Seed | $2.3M | $8.0M | 2016 |
Jee Shin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jee Shin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Calvin Goforth | 2 | 25 |
| Ryan Drant | 1 | 24 |
| R. CALVIN GOFORTH | 1 | 10 |
| Mark Kidd | 1 | 5 |
| Yun Calvin Li | 1 | 2 |
| Douglas Hughes | 1 | 2 |
| Chris Buchko | 1 | 1 |
| Dave Amerson | 1 | 1 |
| Jacob Garfield | 1 | 1 |
| Ryan Calvin Drant | 1 | 1 |
| Beverly Calvin Huss | 1 | 1 |
| Douglas Calvin Hughes | 1 | 1 |
| Chris Calvin Japp | 1 | 1 |
| Noel Calvin Greenberger | 1 | 1 |
| Paul Calvin Atkins | 1 | 1 |
| Joe Catanese | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.